The Department of Veterans Affairs (VA) has awarded Incyte Corporation, a global biopharmaceutical company, a $541 million multiple-award Federal Supply Schedule (FSS) contract and a $3.75 million single-award Blanket Purchase Agreement (BPA) to provide pharmaceutical products, primarily the oncology medication Pemazyre (pemigatinib).
The FSS contract, issued under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB), enables the VA and other federal agencies to acquire Incyte's specialized drug therapies through pre-competed contract terms valid through August 2025. The BPA, also under the FSS-61-IB schedule, focuses specifically on supplying Pemazyre in various dosages to VA medical facilities nationwide through November 2025. Both contract vehicles allow the VA to efficiently procure these critical pharmaceutical products to support healthcare services for eligible veterans across the United States, with no set-aside designations applied.
Generated 3/13/25, 9:56 AM